- Home
- RVPH vs DYAI Comparison
RVPH vs DYAI Comparison
Compare RVPH & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- DYAI
- Stock Information
- Founded
- RVPH 2006
- DYAI 1979
- Country
- RVPH United States
- DYAI United States
- Employees
- RVPH N/A
- DYAI N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- DYAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVPH Health Care
- DYAI Health Care
- Exchange
- RVPH Nasdaq
- DYAI Nasdaq
- Market Cap
- RVPH 36.7M
- DYAI 31.3M
- IPO Year
- RVPH N/A
- DYAI 2004
- Fundamental
- Price
- RVPH $0.90
- DYAI $1.03
- Analyst Decision
- RVPH Strong Buy
- DYAI Strong Buy
- Analyst Count
- RVPH 5
- DYAI 1
- Target Price
- RVPH $9.00
- DYAI $6.00
- AVG Volume (30 Days)
- RVPH 515.2K
- DYAI 46.4K
- Earning Date
- RVPH 05-15-2025
- DYAI 05-14-2025
- Dividend Yield
- RVPH N/A
- DYAI N/A
- EPS Growth
- RVPH N/A
- DYAI N/A
- EPS
- RVPH N/A
- DYAI N/A
- Revenue
- RVPH N/A
- DYAI $3,554,344.00
- Revenue This Year
- RVPH N/A
- DYAI $78.01
- Revenue Next Year
- RVPH N/A
- DYAI N/A
- P/E Ratio
- RVPH N/A
- DYAI N/A
- Revenue Growth
- RVPH N/A
- DYAI 57.59
- 52 Week Low
- RVPH $0.49
- DYAI $0.93
- 52 Week High
- RVPH $4.28
- DYAI $2.67
- Technical
- Relative Strength Index (RSI)
- RVPH 48.40
- DYAI 35.89
- Support Level
- RVPH $0.85
- DYAI $0.95
- Resistance Level
- RVPH $1.15
- DYAI $1.13
- Average True Range (ATR)
- RVPH 0.11
- DYAI 0.08
- MACD
- RVPH 0.00
- DYAI 0.00
- Stochastic Oscillator
- RVPH 33.28
- DYAI 15.00
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About DYAI Dyadic International Inc.
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.